FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingto

on. D.C. 20549	
,	U OMB 4

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* O'Donnell-Tormey Jill					2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]						(Che	elationship o ck all applic Directo	er ner			
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024						Officer below)	Officer (give title below)		Other (specify below)		
COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
(Street) REDWO	OOD C.	A	94065	F	Rule 10b5-1(c) Transaction Indication						Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						ct, instruction or written plan that is intended to satisf				satisfy	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Transaction te onth/Day/	Execution Date		Date,	Code (Instr.				Beneficia Owned F	s Illy ollowing	6. Owners Form: Dir (D) or Ind (I) (Instr.	rect li lirect E 4) C	7. Nature of Indirect Beneficial Ownership	
								Code	Amoun	(A) o	r Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any C		Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	Ov Fo Olly Dir or	vnership rm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		J.11(3)			
Stock Option (Right to Buy)	\$1.76	06/03/2024		A		112,000		(1)	06/03/2034	Common Stock	112,000	\$0	112,00	00	D	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

> /s/ Bryan McMichael, as Attorney-in-Fact for Jill O'Donnell-Tormey

06/05/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.